Forward Pharma A/S reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2016. Net loss for the third quarter ended September 30, 2016 was $11.0 million, or $0.23 per basic and diluted share versus a net loss of $15.8 million, or $0.34 per basic and diluted share for the third quarter of 2015. On a non-GAAP basis, after removing the effect of non-cash income and expense items, the company's third quarter net loss for 2016 would have been $7.3 million, or $0.15 per basic share. Loss before tax was $11.184 million against $15.758 million for the same period a year ago. Operating loss was $10.834 million compared to $15.429 million a year ago. For the nine months, the company reported net loss for the period attributable to ordinary shareholders of the parent of $42.980 million or $0.92 per basic and diluted share compared to $27.423 million or $0.59 per basic and diluted share a year ago. Total comprehensive loss attributable to equity holders of the parent was $38.782 million compared to $44.809 million a year ago. Net cash flows used in operating activities was $27.027 million compared to $24.501 million a year ago. The increase in 2016 in cash used in operating activities is primarily due to an increase in research and development costs. Purchase of equipment was $0.029 million compared to $0.385 million a year ago. Operating loss was $40.129 million compared to $37.364 million a year ago. Net loss before taxes was $43.184 million compared to $27.423 million a year ago.